4//SEC Filing
Freeman Roy Lester 4
Accession 0000950170-25-007742
CIK 0001750149other
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 4:05 PM ET
Size
30.4 KB
Accession
0000950170-25-007742
Insider Transaction Report
Form 4
Freeman Roy Lester
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−6,667→ 0 totalExercise: $4.86Exp: 2029-06-24→ Common Stock (6,667 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−21,854→ 0 totalExercise: $33.43Exp: 2026-07-28→ Common Stock (21,854 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+1,138→ 1,138 totalExercise: $1.26Exp: 2027-12-22→ Common Stock (1,138 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+3,780→ 3,780 totalExercise: $1.26Exp: 2028-06-25→ Common Stock (3,780 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+6,667→ 6,667 totalExercise: $1.26Exp: 2029-06-24→ Common Stock (6,667 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+21,854→ 21,854 totalExercise: $1.26Exp: 2026-07-28→ Common Stock (21,854 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−3,780→ 0 totalExercise: $17.52Exp: 2028-06-25→ Common Stock (3,780 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−6,667→ 0 totalExercise: $3.61Exp: 2030-06-30→ Common Stock (6,667 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−1,138→ 0 totalExercise: $60.00Exp: 2027-12-22→ Common Stock (1,138 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+6,667→ 6,667 totalExercise: $1.26Exp: 2030-06-30→ Common Stock (6,667 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-01-21−30,000→ 0 totalExercise: $1.54Exp: 2031-07-16→ Common Stock (30,000 underlying) - Award
Stock Option (Right to Buy)
2025-01-21+30,000→ 30,000 totalExercise: $1.26Exp: 2031-07-16→ Common Stock (30,000 underlying)
Footnotes (4)
- [F1]The number of shares and the exercise price have been adjusted to reflect a one-for-six reverse stock split of the Issuer's common stock effected on June 30, 2023.
- [F2]The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
- [F3]This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.
- [F4]The acquisition of the reported option was reported in a Form 4 filed on December 29, 2020, which mistakenly reported the expiration date as December 22, 2030.
Documents
Issuer
Inhibikase Therapeutics, Inc.
CIK 0001750149
Entity typeother
Related Parties
1- filerCIK 0001799732
Filing Metadata
- Form type
- 4
- Filed
- Jan 21, 7:00 PM ET
- Accepted
- Jan 22, 4:05 PM ET
- Size
- 30.4 KB